KTKyoko Tsukiyama-Kohara

Kyoko Tsukiyama-Kohara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyoko Tsukiyama-Kohara has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Chieko Kai

    Laboratory of Animal Research Center, Institute of Medical Science, University of Tokyo, Shirokane-dai Minato-Ku, Japan

    4 shared publications
  • Michinori Kohara

    Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku

    4 shared publications
  • Takashi Takano

    Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, Honjo Kumamoto City 2 Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku

    4 shared publications
  • Tomohiro Nishimura

    Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, Honjo Kumamoto City 3 KAKETSUKEN, Kyokushi, Kikuchi, Kumamoto

    4 shared publications
  • Yuri Kasama

    Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, Honjo Kumamoto City

    4 shared publications
  • Makoto Saito

    Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, Honjo Kumamoto City

    3 shared publications

Latest Publications

  • Hepatitis C virus promotes expression of the 3β‐hydroxysterol δ24‐reductase through Sp1

    by Makoto Saito, Michinori Kohara, Kyoko Tsukiyama‐Kohara

    Hepatitis C virus (HCV) establishes chronic infection, which often causes hepatocellular carcinoma. Overexpression of 3β-hydroxysterol Δ24-reductase (DHCR24) by HCV has been shown to impair the p53-mediated cellular response, resulting in tumorigenesis. In the present study, the molecular mechanism by which HCV promotes the expression of DHCR24 was investigated. A significant increase in DHCR24 mRNA transcription was observed in a cell line expressing complete HCV genome, whereas no significant difference in the expression of DHCR24 was seen in cell lines expressing individual viral proteins. The 5′-flanking genomic region of DHCR24 was characterized to explore the genomic region and host factor(s) involved in the transcriptional regulation of DHCR24. As a result, the HCV response element (−167/−140) was identified, which contains AP-2α, MZF-1, and Sp1 binding motifs. The binding affinity of the host factor to this response element was increased in nuclear extracts from cells infected with HCV and corresponded with augmented affinity of Sp1. Both mithramycin A (Sp1 inhibitor) and small interfering RNA targeting Sp1 prevented the binding of host factors to the response element. Silencing of Sp1 also downregulated the increased expression of DHCR24. The binding affinity of Sp1 to the response element was augmented by oxidative stress, whereas upregulation of DHCR24 in cells expressing HCV was blocked significantly by a reactive oxygen species scavenger. Elevated phosphorylation of Sp1 in response to oxidative stress was mediated by the ATM kinase. Thus, activation of Sp1 by oxidative stress is involved in the promotion of expression of DHCR24 by HCV. J. Med. Virol. 84:733–746, 2012.


  • Open Access

    Monoclonal Antibody 2-152a Suppresses Hepatitis C Virus Infection Through Betaine/GABA Transporter-1

    by Masaaki Satoh, Makoto Saito, Takashi Takano, Yuri Kasama, Tomohiro Nishimura, Yasumasa Nishito, Yuichi Hirata, Masaaki Arai, Masayuki Sudoh, Chieko Kai, et al.

    Background. We recently established a monoclonal antibody (2-152a MAb) that binds to 3β-hydroxysterol-Δ24-reductase (DHCR24) by immunizing mice with cells (RzM6-LC) persistently expressing hepatitis C virus (HCV). Here, we aimed to analyze the activity of 2-152a MAb against HCV replication and explore the molecular mechanism underlying the antiviral activity. Methods. We characterized the effects of 2-152a MAb on HCV replication and performed a microarray analysis of antibody-treated HCV replicon cells. The molecules showing a significant change after the antibody treatment were screened to examine their relationship with HCV replication. Results. The antibody had antiviral activity both in vitro and in vivo (chimeric mice). In the microarray analysis, 2-152a MAb significantly suppressed the expression of betaine/GABA transporter-1 (BGT-1) in 2 HCV replicon cell lines but not in HCV-cured cells. Silencing of BGT-1 expression by small interfering RNA (siRNA) revealed significant suppression of HCV replication and infection without cytotoxicity. Further, BGT-1 expression was significantly increased in the presence of HCV (P < .05). Conclusions. Our results suggest that 2-152a MAb suppresses HCV replication and infection through BGT-1. These findings highlight important roles of BGT-1 in HCV replication and reveal a possible target for anti-HCV therapy.


  • Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes

    by Takashi Takano, Kyoko Tsukiyama-Kohara, Masahiro Hayashi, Yuichi Hirata, Masaaki Satoh, Yuko Tokunaga, Chise Tateno, Yukiko Hayashi, Tsunekazu Hishima, Nobuaki Funata, et al.


  • Open Access

    Hepatitis C Virus-Related Lymphomagenesis in a Mouse Model

    by Kyoko Tsukiyama-Kohara, Satoshi Sekiguchi, Yuri Kasama, Nagla Elwy Salem, Keigo Machida, Michinori Kohara

    B cell non-Hodgkin lymphoma is a typical extrahepatic manifestation frequently associated with hepatitis C virus (HCV) infection. The mechanism by which HCV infection leads to lymphoproliferative disorder remains unclear. Our group established HCV transgenic mice that expressed the full HCV genome in B cells (RzCD19Cre mice). We observed a 25.0% incidence of diffuse large B cell non-Hodgkin lymphomas (22.2% in male and 29.6% in female mice) within 600 days of birth. Interestingly, RzCD19Cre mice with substantially elevated serum-soluble interleukin-2 receptor α-subunit (sIL-2Rα) levels (>1000 pg/mL) developed B cell lymphomas. Another mouse model of lymphoproliferative disorder was established by persistent expression of HCV structural proteins through disruption of interferon regulatory factor-1 (irf-1_/_/CN2 mice). Irf-1_/_/CN2 mice showed extremely high incidences of lymphomas and lymphoproliferative disorders. Moreover, these mice showed increased levels of interleukin (IL)-2, IL-10, and Bcl-2 as well as increased Bcl-2 expression, which promoted oncogenic transformation of lymphocytes.


  • Translocase of outer mitochondrial membrane 70 expression is induced by hepatitis C virus and is related to the apoptotic response

    by Takashi Takano, Michinori Kohara, Yuri Kasama, Tomohiro Nishimura, Makoto Saito, Chieko Kai, Kyoko Tsukiyama‐Kohara

    The localization of hepatitis C virus (HCV) proteins in cells leads to several problems. The translocase of outer mitochondrial membrane 70 (TOM70) is a mitochondrial import receptor. In this study, TOM70 expression was induced by HCV infection. TOM70 overexpression induced resistance to tumor necrosis factor‐alpha (TNF‐α)‐mediated apoptosis but not to Fas‐induced apoptosis in HepG2 cells. TOM70 was found to be induced by the HCV non‐structural protein (NS)3/4A protein, and silencing of TOM70 decreased the levels of the NS3 and Mcl‐1 proteins. These results indicate that TOM70 can directly interact with the NS3 protein. In hepatoma cells, silencing of TOM70 induced apoptosis and increased caspase‐3/7 activity but did not modify caspase‐8 and caspase‐9 activity. TOM70 silencing‐induced apoptosis was impaired in HCV NS3/4A protein‐expressing cells. Thus, this study revealed a novel finding, that is, TOM70 is linked with the NS3 protein and the apoptotic response. J. Med. Virol. 83:801–809, 2011.


  • Open Access

    Hepatitis C Virus Impairs p53 via Persistent Overexpression of 3β-Hydroxysterol Δ24-Reductase

    by Tomohiro Nishimura, Michinori Kohara, Kosuke Izumi, Yuri Kasama, Yuichi Hirata, Ying Huang, Masahiro Shuda, Chise Mukaidani, Takashi Takano, Yuko Tokunaga, et al.


  • Hepatitis C virus-core protein facilitates the degradation of Ku70 and reduces DNA-PK activity in hepatocytes

    by Kentarou Saitou, Kiyohisa Mizumoto, Tomohiro Nishimura, Chieko Kai, Kyoko Tsukiyama-Kohara